<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00888381</url>
  </required_header>
  <id_info>
    <org_study_id>CSLCT-NHF-09-57</org_study_id>
    <secondary_id>2009-011450-18</secondary_id>
    <nct_id>NCT00888381</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers</brief_title>
  <official_title>A Phase IV, Single-centre, Open-label Study to Evaluate the Immunogenicity and Safety of the 2009/2010 Formulation of the Enzira® Vaccine in Two Groups of Healthy Volunteers: 'Adults' (Aged ≥ 18 to &lt; 60 Years) and 'Older Adults' (Aged ≥ 60 Years).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy and safety of CSL's 2009/2010 formulation
      of the Enzira vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.</measure>
    <time_frame>Approximately 21 days after vaccination</time_frame>
    <description>As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion is defined as achieving a post-vaccination titre of ≥ 40 for those participants with a pre-vaccination HI titre of &lt; 10; significant increase is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of ≥ 10.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.</measure>
    <time_frame>Approximately 21 days after vaccination</time_frame>
    <description>GMFI is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.</measure>
    <time_frame>Approximately 21 days after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Frequency of Any Solicited Local Reactions.</measure>
    <time_frame>During the 4 days after vaccination (Day 0 plus 3 days)</time_frame>
    <description>The number of participants reporting any solicited local reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Frequency of Any Solicited Systemic Symptoms.</measure>
    <time_frame>During the 4 days after vaccination (Day 0 plus 3 days)</time_frame>
    <description>The number of participants reporting any solicited systemic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Incidence of Any Unsolicited Adverse Events (AEs).</measure>
    <time_frame>After vaccination until the end of the study; approximately 21 days</time_frame>
    <description>The number of participants reporting any unsolicited adverse events.
Unsolicited adverse event (UAE) grading:
Mild: Symptoms were easily tolerated and did not interfere with normal, everyday activities. Moderate: Enough discomfort to have caused some interference with normal, everyday activities. Severe: Symptoms that prevented normal, everyday activities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers aged 18 to 59 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Older Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers aged 60 years or older</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Influenza Vaccine (2009 / 2010 formulation)</intervention_name>
    <description>A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.</description>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_label>Older Adults</arm_group_label>
    <other_name>Enzira® vaccine (2009 / 2010 formulation)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged ≥ 18 years at the time of providing informed consent

          -  Participants are capable of understanding the purposes and risks of the study and are
             able to provide written informed consent

          -  Willing and able to adhere to all protocol requirements

          -  Able to provide a sample of approximately 17 mL of venous blood on two separate
             occasions without undue distress/discomfort

          -  Females of child bearing potential (i.e. ovulating, pre-menopausal, not surgically
             sterile) must be abstinent or be willing to use a medically accepted contraceptive
             regimen for the duration of the study

        Exclusion Criteria:

          -  Known hypersensitivity to a previous dose of influenza vaccine or allergy to eggs,
             chicken protein, neomycin, polymyxin, or any components of the Enzira® vaccine

          -  Clinical signs of an active infection and/or an elevated oral temperature (≥ 38.0°C)
             at study entry

          -  A clinically significant medical or psychiatric condition

          -  A confirmed or suspected immunosuppressive condition

          -  History of seizures

          -  History of Guillain-Barré Syndrome

          -  Vaccination with a seasonal influenza virus vaccine or with an experimental influenza
             virus vaccine in the 6 months preceding study entry

          -  Currently receiving treatment with radiotherapy or cytotoxic drugs, or have received
             such treatment within the 6 months preceding administration of Enzira® vaccine

          -  Currently receiving systemic glucocorticoid therapy (excluding topical or inhaled
             preparations) or have received such therapy within the 3 months preceding study entry

          -  Currently receiving immunoglobulins and/or any blood products or have received such
             treatment within the 3 months preceding the administration of Enzira® vaccine

          -  Currently participating in another investigational study or recent study participation
             ending 3 months preceding administration of Enzira® vaccine

          -  Currently receiving treatment with warfarin or other anticoagulants

          -  Evidence or history of substance or alcohol abuse within the 12 months before study
             entry

          -  Females of child bearing potential who are planning to become pregnant or planning to
             discontinue contraceptive precautions during the study period

          -  Females who are pregnant or lactating

          -  Any issues that, in the opinion of the investigator, would render the subject
             unsuitable for study participation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director Vaccines</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiltern (Early Phase) Limited. Ninewells Hospital and Medical School</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2009</study_first_submitted>
  <study_first_submitted_qc>April 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2009</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 13, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 18, 2012</results_first_posted>
  <last_update_submitted>October 23, 2017</last_update_submitted>
  <last_update_submitted_qc>October 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Adults</title>
          <description>Healthy volunteers aged 18 to 59 years</description>
        </group>
        <group group_id="P2">
          <title>Older Adults</title>
          <description>Healthy volunteers aged 60 years or older</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adults</title>
          <description>Healthy volunteers aged 18 to 59 years</description>
        </group>
        <group group_id="B2">
          <title>Older Adults</title>
          <description>Healthy volunteers aged 60 years or older</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="60"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.3" spread="12.31"/>
                    <measurement group_id="B2" value="66.2" spread="5.92"/>
                    <measurement group_id="B3" value="50.7" spread="18.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.</title>
        <description>As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion is defined as achieving a post-vaccination titre of ≥ 40 for those participants with a pre-vaccination HI titre of &lt; 10; significant increase is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of ≥ 10.</description>
        <time_frame>Approximately 21 days after vaccination</time_frame>
        <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Evaluable Participants Achieving Seroconversion or Significant Increase in Antibody Titre.</title>
          <description>As per the criteria specified in the CPMP/BWP/214/96 Note for Guidance on Harmonisation of Requirements for Influenza Vaccines. For haemagglutination inhibition (HI), seroconversion is defined as achieving a post-vaccination titre of ≥ 40 for those participants with a pre-vaccination HI titre of &lt; 10; significant increase is defined as a four-fold or greater increase in HI titre for those participants with a pre-vaccination HI titre of ≥ 10.</description>
          <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane/59/2007 (H1N1) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="81.6" upper_limit="97.2"/>
                    <measurement group_id="O2" value="53.4" lower_limit="39.9" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane/10/2007 (H3N2) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="83.8" upper_limit="98.2"/>
                    <measurement group_id="O2" value="63.8" lower_limit="50.1" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="64.0" upper_limit="86.6"/>
                    <measurement group_id="O2" value="46.6" lower_limit="33.3" upper_limit="60.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.</title>
        <description>GMFI is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
        <time_frame>Approximately 21 days after vaccination</time_frame>
        <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Geometric Mean Fold Increase (GMFI) in Antibody Titre After Vaccination.</title>
          <description>GMFI is defined as the geometric mean of the fold increases of post-vaccination antibody titre over the pre-vaccination antibody titre.</description>
          <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane/59/2007 (H1N1) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.86" lower_limit="19.339" upper_limit="40.129"/>
                    <measurement group_id="O2" value="5.02" lower_limit="3.575" upper_limit="7.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane/10/2007( H3N2) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.32" lower_limit="21.003" upper_limit="43.772"/>
                    <measurement group_id="O2" value="9.80" lower_limit="6.105" upper_limit="15.738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.85" lower_limit="9.333" upper_limit="17.683"/>
                    <measurement group_id="O2" value="6.13" lower_limit="4.121" upper_limit="9.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.</title>
        <time_frame>Approximately 21 days after vaccination</time_frame>
        <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Evaluable Participants Achieving a HI Titre ≥ 40 or Single Radial Haemolysis (SRH) Area ≥ 25 mm2.</title>
          <population>The Evaluable Population comprised all participants who were vaccinated with the study vaccine, provided both pre- and post-vaccination antibody titre results, and were not excluded from the analyses (eg, for the use of a prohibited medication or a laboratory-confirmed influenza virus infection between Visits 1 and 2).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/Brisbane/59/2007 (H1N1) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="91.4" lower_limit="81.0" upper_limit="97.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/Brisbane/10/2007( H3N2) - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="94.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="94.8" lower_limit="85.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Brisbane/60/2008 - like strain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.0" lower_limit="73.4" upper_limit="92.9"/>
                    <measurement group_id="O2" value="60.3" lower_limit="46.6" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Frequency of Any Solicited Local Reactions.</title>
        <description>The number of participants reporting any solicited local reactions.</description>
        <time_frame>During the 4 days after vaccination (Day 0 plus 3 days)</time_frame>
        <population>The Safety Population comprised all participants who received study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Any Solicited Local Reactions.</title>
          <description>The number of participants reporting any solicited local reactions.</description>
          <population>The Safety Population comprised all participants who received study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any induration larger than 50 mm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any ecchymosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Frequency of Any Solicited Systemic Symptoms.</title>
        <description>The number of participants reporting any solicited systemic symptoms.</description>
        <time_frame>During the 4 days after vaccination (Day 0 plus 3 days)</time_frame>
        <population>The Safety Population comprised all participants who received study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Any Solicited Systemic Symptoms.</title>
          <description>The number of participants reporting any solicited systemic symptoms.</description>
          <population>The Safety Population comprised all participants who received study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited systemic symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any temperature above 38°C for 24 hours or longer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Incidence of Any Unsolicited Adverse Events (AEs).</title>
        <description>The number of participants reporting any unsolicited adverse events.
Unsolicited adverse event (UAE) grading:
Mild: Symptoms were easily tolerated and did not interfere with normal, everyday activities. Moderate: Enough discomfort to have caused some interference with normal, everyday activities. Severe: Symptoms that prevented normal, everyday activities.</description>
        <time_frame>After vaccination until the end of the study; approximately 21 days</time_frame>
        <population>The Safety Population comprised all participants who received study vaccine.</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Healthy volunteers aged 18 to 59 years</description>
          </group>
          <group group_id="O2">
            <title>Older Adults</title>
            <description>Healthy volunteers aged 60 years or older</description>
          </group>
        </group_list>
        <measure>
          <title>The Incidence of Any Unsolicited Adverse Events (AEs).</title>
          <description>The number of participants reporting any unsolicited adverse events.
Unsolicited adverse event (UAE) grading:
Mild: Symptoms were easily tolerated and did not interfere with normal, everyday activities. Moderate: Enough discomfort to have caused some interference with normal, everyday activities. Severe: Symptoms that prevented normal, everyday activities.</description>
          <population>The Safety Population comprised all participants who received study vaccine.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of participants with at least one UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reporting mild UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reporting moderate UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of participants reporting severe UAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 21 days after study vaccination for serious adverse events and unsolicited adverse events.</time_frame>
      <desc>The Safety Population comprised all participants who received study vaccine.
Other adverse events presented were unsolicited adverse events up to approximately 21 days after study vaccination.</desc>
      <group_list>
        <group group_id="E1">
          <title>Adults</title>
          <description>Healthy volunteers aged 18 to 59 years</description>
        </group>
        <group group_id="E2">
          <title>Older Adults</title>
          <description>Healthy volunteers aged 60 years or older</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="60"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CSL agreements and restrictions on publishing may vary with individual investigators; however, CSL will not prohibit any investigator from publishing. CSL supports the publication of results from all centers of a multi-center trial and generally requires that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Study Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>Use email contact</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

